278 related articles for article (PubMed ID: 24800886)
1. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
3. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
[TBL] [Abstract][Full Text] [Related]
4. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
Valiulienė G; Vitkevičienė A; Navakauskienė R
Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
[TBL] [Abstract][Full Text] [Related]
5. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
7. Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy.
Valiulienė G; Treigytė G; Savickienė J; Matuzevičius D; Alksnė M; Jarašienė-Burinskaja R; Bukelskienė V; Navakauskas D; Navakauskienė R
Biomed Pharmacother; 2016 Apr; 79():62-70. PubMed ID: 27044813
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
9. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-
Sunami Y; Araki M; Kan S; Ito A; Hironaka Y; Imai M; Morishita S; Ohsaka A; Komatsu N
J Biol Chem; 2017 Feb; 292(7):2815-2829. PubMed ID: 28053092
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
11. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
[TBL] [Abstract][Full Text] [Related]
12. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells.
Savickiene J; Treigyte G; Borutinskaite VV; Navakauskiene R
Cell Mol Biol Lett; 2012 Dec; 17(4):501-25. PubMed ID: 22820861
[TBL] [Abstract][Full Text] [Related]
13. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
[TBL] [Abstract][Full Text] [Related]
14. Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells.
Hennig D; Müller S; Wichmann C; Drube S; Pietschmann K; Pelzl L; Grez M; Bug G; Heinzel T; Krämer OH
Br J Cancer; 2015 Jan; 112(2):329-37. PubMed ID: 25514379
[TBL] [Abstract][Full Text] [Related]
15. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.
Kusaczuk M; Krętowski R; Stypułkowska A; Cechowska-Pasko M
Invest New Drugs; 2016 Oct; 34(5):552-64. PubMed ID: 27468826
[TBL] [Abstract][Full Text] [Related]
17. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
19. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
20. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
